SECINPHA Stock Latest News
Company AnnouncementsCinclus Pharma Adjusts Share Capital to Support Future Incentive Programs3d ago
Company AnnouncementsCinclus Pharma Sets Date for Q3 2026 Report and Investor Presentation4d ago
Company AnnouncementsCinclus Pharma Sets Nomination Committee Ahead of 2027 AGM6d ago
Company AnnouncementsCinclus Pharma Steps Up Investor Outreach as GERD Drug Enters Late-Stage Trials1w ago- Company AnnouncementsCinclus Pharma Issues and Repurchases Class C Shares for Long-Term Incentive Program3w ago
Company AnnouncementsCinclus Pharma Phase I Data Show Strong Acid Control for GERD Candidate4w ago
Company AnnouncementsCinclus Pharma Details 2026 Interim Progress and Market Focus2M ago
Company AnnouncementsCinclus Pharma sets August 19 date for Q2 2026 results presentation2M ago
Company AnnouncementsCinclus Pharma Hits Phase III Enrollment Milestone in Severe GERD Trial4M ago
Company AnnouncementsCinclus Pharma Advances Linaprazan Glurate Heart‑Safety Study, Keeping GERD Pipeline on Track4M ago
Company AnnouncementsCinclus Pharma Hits Phase III Milestone in Erosive GERD Trial5M agoCompany AnnouncementsCinclus Pharma Withdraws Key Phase 3 GERD Trial, Resetting Expectations for Linaprazan Glurate5M ago
- Company AnnouncementsCinclus Pharma Publishes Q1 2026 Interim Report Highlighting Late-Stage Pipeline and Market Potential5M ago
Company AnnouncementsCinclus Pharma Sets May 13 Webcast for First-Quarter 2026 Report6M ago
Company AnnouncementsCinclus Pharma Calls 2026 AGM, Sets Rules for Shareholder Participation6M ago
Company AnnouncementsCinclus Pharma Ramps Up Investor Outreach Ahead of Late-Stage GERD Drug Push7M ago
Company AnnouncementsCinclus Pharma Secures Up to EUR 28 Million to Accelerate Late-Stage Acid-Reflux Drug7M agoCompany AnnouncementsCinclus Pharma Gains Boost as FDA Backs Single Pivotal Study Path for GERD Drug8M ago
